Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
European Journal of Trauma and Emergency Surgery

11-04-2024 | Safinamide | Original Article

Beyond expectations: safinamide’s unprecedented neuroprotective impact on acute spinal cord injury

Author: Murat Gökten

Published in: European Journal of Trauma and Emergency Surgery

Login to get access

Abstract

Background

Traumatic spinal cord injury (SCI) is the most common preventable cause of morbidity. Despite rapid advances in medicine, effective pharmacological treatment against SCI has not yet been confirmed. This study aimed to investigate the possible anti-inflammatory, antiapoptotic, and neuroprotective effects of safinamide after SCI in a rat model.

Methods

A total of 40 male Wistar albino rats were randomly divided into four groups. Group 1 underwent only laminectomy. Group 2 underwent SCI after laminectomy. In group 3, SCI was performed after laminectomy, and immediately afterward, intraperitoneal physiological saline solution was administered. In group 4, SCI was performed after laminectomy, and 90 mg/kg of safinamide was given intraperitoneally immediately afterward. Moderate spinal cord damage was induced at the level of thoracic vertebra nine (T9). Neuromotor function tests were performed and levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) were measured. In both serum and spinal cord tissue, immunohistochemistry and histopathology studies were also conducted.

Results

TNF-α, IL-1β, and IL-6 levels were found to be significantly increased in group 2 and group 3. In group 4, these levels were statistically significantly decreased. Group 4 also exhibited significant improvement in neuromotor function tests compared to the other groups. Histopathologically, it was found that group 4 showed significantly reduced inflammation and apoptosis compared to the other groups.

Conclusion

This study revealed that safinamide has neuroprotective effects against SCI due to its anti-inflammatory, antiapoptotic, and antioxidant activities.
Literature
1.
Mortezaee K, et al. Inflammasome: its role in traumatic brain and spinal cord injury. J Cell Physiol. 2018;233(7):5160–9.CrossRefPubMed
2.
3.
Bloom O, Herman PE, Spungen AM. Systemic inflammation in traumatic spinal cord injury. Exp Neurol. 2020;325:113143.CrossRefPubMed
4.
5.
6.
Boz PB, et al. The effect of neutrophil to lymphocyte and neutrophil to platelet ratios on prognosis in stroke patients. Dicle Tıp Dergisi. 2022;49(4):558–64.CrossRef
7.
Hachem LD, Fehlings MG. Pathophysiology of spinal cord injury. Neurosurgery Clinics. 2021;32(3):305–13.PubMed
8.
Fabbri M, Rosa MM, Ferreira JJ. Clinical pharmacology review of opicapone for the treatment of Parkinson’s disease. Neurodegener Dis Manag. 2016;6(5):349–62.CrossRefPubMed
9.
10.
Müller T, Foley P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet. 2017;56(3):251–61.CrossRefPubMed
11.
Giossi R, et al. Overall efficacy and safety of safinamide in Parkinson’s disease: a systematic review and a meta-analysis. Clin Drug Investig. 2021;41:321–39.CrossRefPubMedPubMedCentral
12.
Pisanò CA, et al. Safinamide inhibits in vivo glutamate release in a rat model of Parkinson’s disease. Neuropharmacology. 2020;167:108006.CrossRefPubMed
13.
Sadeghian M, et al. Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson’s disease. Neuropathol Appl Neurobiol. 2016;42(5):423–35.CrossRefPubMed
14.
Shi X, et al. Behavioral assessment of sensory, motor, emotion, and cognition in rodent models of intracerebral hemorrhage. Front Neurol. 2021;12:667511.CrossRefPubMedPubMedCentral
15.
Hausser N., et al., Detecting behavioral deficits in rats after traumatic brain injury. J Vis Exp, 2018;(131).
16.
Tan WJ, et al. MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression. J Clin Pathol. 2016;69(10):858–65.CrossRefPubMed
17.
Nardone R, et al. Descending motor pathways and cortical physiology after spinal cord injury assessed by transcranial magnetic stimulation: a systematic review. Brain Res. 2015;1619:139–54.CrossRefPubMed
18.
Arac D, et al. Neuroprotective effects of milrinone on experimental acute spinal cord injury: rat model. World Neurosurgery. 2021;147:e225–33.CrossRefPubMed
19.
Morari M, et al. Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia. J Pharmacol Exp Ther. 2018;364(2):198–206.CrossRefPubMed
20.
Blair HA, Dhillon S. Safinamide: a review in Parkinson’s disease. CNS Drugs. 2017;31(2):169–76.CrossRefPubMed
21.
22.
Jenkins RH, et al. Unravelling the broader complexity of IL-6 involvement in health and disease. Cytokine. 2021;148:155684.CrossRefPubMed
23.
Xu T, et al. The protective effect of safinamide in ischemic stroke mice and a brain endothelial cell line. Neurotox Res. 2020;38(3):733–40.CrossRefPubMed
24.
Metadata
Title
Beyond expectations: safinamide’s unprecedented neuroprotective impact on acute spinal cord injury
Author
Murat Gökten
Publication date
11-04-2024
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Trauma and Emergency Surgery
Print ISSN: 1863-9933
Electronic ISSN: 1863-9941
DOI
https://doi.org/10.1007/s00068-024-02513-y